A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
One current hypothesis as to what limits duration of initial hormone response is the rapid
emergence of hormone resistant prostate carcinoma cells. Suramin has shown effectiveness as a
treatment for hormonally refractory prostate carcinoma. Survival was less in patients with
high rather than low circulating androgen levels. Thus, suramin might slow the emergence of
hormone refractory tumor cells while combined androgen ablation may maximize the
effectiveness of suramin. In this trial, we will pilot this concept.